Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Simone Brogi, Rita Tabanelli & Vincenzo Calderone. (2022) Combinatorial approaches for novel cardiovascular drug discovery: a review of the literature. Expert Opinion on Drug Discovery 17:10, pages 1111-1129.
Read now
Read now
Harold E Bays, David Neff, Joanne E Tomassini & Andrew M Tershakovec. (2008) Ezetimibe: cholesterol lowering and beyond. Expert Review of Cardiovascular Therapy 6:4, pages 447-470.
Read now
Read now
Harold E Bays, Ann P Tighe, Richard Sadovsky & Michael H Davidson. (2008) Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Review of Cardiovascular Therapy 6:3, pages 391-409.
Read now
Read now
Harold Bays, Lawrence Blonde & Robert Rosenson. (2006) Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?. Expert Review of Cardiovascular Therapy 4:6, pages 871-895.
Read now
Read now
Harold Bays & Christie Ballantyne. (2006) Adiposopathy: why do adiposity and obesity cause metabolic disease?. Future Lipidology 1:4, pages 389-420.
Read now
Read now
James A Sikorski. (2006) Cholesteryl ester transfer protein inhibitors as potential new therapies for coronary artery disease. Expert Opinion on Therapeutic Patents 16:6, pages 753-772.
Read now
Read now
Articles from other publishers (21)
N. Jeelan Basha, S. M. Basavarajaiah & K. Shyamsunder. (2022) Therapeutic potential of pyrrole and pyrrolidine analogs: an update. Molecular Diversity 26:5, pages 2915-2937.
Crossref
Crossref
Harold E. Bays. (2016) A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals. Journal of Clinical Lipidology 10:2, pages 240-264.
Crossref
Crossref
Harold E. Bays, Peter H. Jones, Terry A. Jacobson, David E. Cohen, Carl E. Orringer, Shanu Kothari, Dan E. Azagury, John Morton, Ninh T. Nguyen, Eric C. Westman, Deborah B. Horn, Wendy Scinta & Craig Primack. (2016) Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: EXECUTIVE SUMMARY. Journal of Clinical Lipidology 10:1, pages 15-32.
Crossref
Crossref
Harold E. Bays, Peter H. Jones, Terry A. Jacobson, David E. Cohen, Carl E. Orringer, Shanu Kothari, Dan E. Azagury, John Morton, Ninh T. Nguyen, Eric C. Westman, Deborah B. Horn, Wendy Scinta & Craig Primack. (2016) Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT. Journal of Clinical Lipidology 10:1, pages 33-57.
Crossref
Crossref
Harold E. Bays, Peter H. Jones, Carl E. Orringer, W. Virgil Brown & Terry A. Jacobson. (2016) National Lipid Association Annual Summary of Clinical Lipidology 2016. Journal of Clinical Lipidology 10:1, pages S1-S43.
Crossref
Crossref
Harold E. Bays, Peter H. Jones, W. Virgil Brown & Terry A. Jacobson. (2014) National Lipid Association Annual Summary of Clinical Lipidology 2015. Journal of Clinical Lipidology 8:6, pages S1-S36.
Crossref
Crossref
Yu Kataoka & Stephen J. Nicholls. (2014) Atherosclerotic Plaque Imaging for Evaluation of HDL Targeting Therapy. Journal of the Japanese Coronary Association 20:4, pages 282-294.
Crossref
Crossref
Harold Bays. 2014. Lipoproteins in Diabetes Mellitus. Lipoproteins in Diabetes Mellitus
415
433
.
W. Virgil Brown, Harold E. Bays, Kevin C. Maki & Robert A. Wild. (2012) Planning a clinical trial. Journal of Clinical Lipidology 6:6, pages 484-495.
Crossref
Crossref
Azhar S. SulaimanNada F. ZakiWasif S. Gillani. (2010) Combined Therapy in Dyslipidemia and Hyperglicemia of Diabetes Mellitus Type II. Clinical Medicine Insights: Therapeutics 2, pages CMT.S5220.
Crossref
Crossref
Harold E. Bays. (2009) “Sick Fat,” Metabolic Disease, and Atherosclerosis. The American Journal of Medicine 122:1, pages S26-S37.
Crossref
Crossref
Harold Bays. 2009. Clinical Lipidology. Clinical Lipidology
530
543
.
Harold E Bays & Ronald B Goldberg. (2007) The ‘Forgotten’ Bile Acid Sequestrants: Is Now a Good Time to Remember?. American Journal of Therapeutics 14:6, pages 567-580.
Crossref
Crossref
William C. Cromwell, Harold E. Bays & Peter P. Toth. 2007. Markers in Cardiology. Markers in Cardiology
217
250
.
Sandra J. Lewis. (2007) Perspectives and current strategies for dyslipidemia in women. Current Cardiovascular Risk Reports 1:2, pages 159-166.
Crossref
Crossref
R. P. F. Dullaart, G. M. Dallinga-Thie, B. H. R. Wolffenbuttel & A. van Tol. (2007) CETP inhibition in cardiovascular risk management: a critical appraisal. European Journal of Clinical Investigation 37:2, pages 90-98.
Crossref
Crossref
Daniel J Rader. (2007) Mechanisms of Disease: HDL metabolism as a target for novel therapies. Nature Clinical Practice Cardiovascular Medicine 4:2, pages 102-109.
Crossref
Crossref
Michael H. Davidson. 2007. Cardiovascular Therapeutics. Cardiovascular Therapeutics
515
527
.
Michael H. Davidson. 2007. Therapeutic Lipidology. Therapeutic Lipidology
121
148
.
Harold E. Bays. 2007. Therapeutic Lipidology. Therapeutic Lipidology
221
240
.
Daniel J. Rader. (2006) Molecular regulation of HDL metabolism and function: implications for novel therapies. Journal of Clinical Investigation 116:12, pages 3090-3100.
Crossref
Crossref